ArticleBMC nephrology2026
Association of high-density lipoprotein cholesterol lipid with peritoneal dialysis related peritonitis.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between high-density lipoprotein cholesterol (HDL-C) concentrations and the risk of peritoneal dialysis-related peritonitis (PDRP) remains unclear. We aimed to examine the association between HDL-C concentrations and the risk of new-onset PDRP in patients undergoing maintenance peritoneal dialysis (PD), while investigating potential modifying factors that may influence this relationship.
methodsThis retrospective cohort study included 512 eligible patients with maintenance PD recruited from January 1, 2010 to December 31, 2020 at the Peritoneal Dialysis Center of Nanfang Hospital. The study outcome was the new-onset PDRP. Cox proportional hazards models were used to examine the association between baseline HDL-C and new-onset PDRP.
resultsDuring a median follow-up of 45 months, 156 incident peritonitis cases (30.5%) were recorded. There was a significantly inverse association between HDL-C concentrations and the risk of new-onset PDRP (per SD increment, adjusted HR = 0.67, 95%CI: 0.51, 0.88). Compared with patients with low HDL-C ( < 40 mg/dL), those with normal (40-60 mg/dL) and high (≥60 mg/dL) HDL-C concentrations had a 35% (adjusted HR = 0.65, 95%CI: 0.43, 0.98) and 60% (adjusted HR = 0.40, 95%CI: 0.18, 0.87) lower risk of new-onset PDRP, respectively. The inverse association between elevated HDL-C concentrations and reduced PDRP risk persisted consistently across all examined subgroups, including those stratified by age, sex, BMI, diabetes status, cardiovascular disease, dialysis vintage, total weekly Kt/V, and C-reactive protein concentrations (all P-interaction > 0.05)
conclusionHigher HDL-C concentrations were independently associated with reduced PDRP risk in maintenance PD patients, suggesting HDL-C may serve as a potential protective marker against peritonitis in this population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.